Agilent Technologies, Inc. (NYSE:A) had its price objective raised by Barclays PLC from $67.00 to $71.00 in a report issued on Tuesday. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays PLC’s price target points to a potential upside of 1.49% from the stock’s previous close.
A has been the topic of a number of other reports. Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research report on Tuesday, November 14th. Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Bank of America Corporation reiterated an “equal weight” rating on shares of Agilent Technologies in a research report on Tuesday, August 15th. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Deutsche Bank AG set a $68.00 target price on Agilent Technologies and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Agilent Technologies currently has a consensus rating of “Buy” and a consensus target price of $67.84.
Agilent Technologies (A) traded up $1.17 during trading on Tuesday, hitting $69.96. The company had a trading volume of 4,141,100 shares, compared to its average volume of 1,836,956. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.76 and a current ratio of 3.22. Agilent Technologies has a 12-month low of $42.92 and a 12-month high of $70.23. The stock has a market capitalization of $22,520.00, a P/E ratio of 30.04, a PEG ratio of 2.70 and a beta of 1.28.
In other Agilent Technologies news, insider Patrick Kaltenbach sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $63.26, for a total transaction of $316,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael R. Mcmullen sold 22,481 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $68.77, for a total value of $1,546,018.37. Following the sale, the chief executive officer now owns 336,637 shares of the company’s stock, valued at $23,150,526.49. The disclosure for this sale can be found here. Insiders sold 90,228 shares of company stock valued at $5,938,206 over the last quarter.
A number of large investors have recently made changes to their positions in A. JPMorgan Chase & Co. boosted its position in shares of Agilent Technologies by 45.2% in the second quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock worth $720,358,000 after buying an additional 3,779,099 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Agilent Technologies by 720.6% in the second quarter. PNC Financial Services Group Inc. now owns 1,131,276 shares of the medical research company’s stock worth $67,097,000 after buying an additional 993,414 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Agilent Technologies in the second quarter worth about $58,693,000. TimesSquare Capital Management LLC purchased a new stake in shares of Agilent Technologies in the third quarter worth about $58,550,000. Finally, Voya Investment Management LLC boosted its position in shares of Agilent Technologies by 444.0% in the second quarter. Voya Investment Management LLC now owns 1,032,128 shares of the medical research company’s stock worth $61,215,000 after buying an additional 842,398 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.